Skip to content Skip to footer
Subscribe Now

VIEWPOINTS

VIEWPOINTS_Matthew Robinson_2023
Matthew Robinson, CTO, Immunome Shares Insights on Strategic Collaboration with AbbVie to Identify Multiple Novel Oncology Targets
Shots: Matthew spoke about Immunome’s collaboration and option agreement with AbbVie for the discovery of up to 10 novel antibody-target pairs arising from three specified tumor types using Immunome’s Discovery Engine He also talked about how the partnership with AbbVie can support Immunome’s strategy to maximize the new drug discovery potential of its Discovery Engine…
May 8, 2023
VIEWPOINTS_Mark Cobbold1_Carsten Linnemann2 _2023
Mark Cobbold and Carsten Linnemann Share Insights on Neogene Therapeutics’ Acquisition
Shots: Carsten gave the details of the agreement with Neogene Therapeutics to bring cell therapies to patients with solid tumors through Neogene’s next-generation T-cell receptor therapies. He also talked about Neogene’s TCR discovery platform Mark spoke about how this acquisition provides AstraZeneca with a unique opportunity to bring innovative science and leading experts in T-cell…
May 4, 2023
VIEWPOINTS_Rick Hawkins1_John McKew Share2_2023
Rick Hawkins and John McKew Share Views on Interim P-II Data from the Two Trials Evaluating LUM-201 for Moderate Pediatric Growth Hormone Deficiency
Shots: Rick and John spoke about the trial design and the results from the P-II OraGrowtH210 Trial and P-II OraGrowtH212 trial evaluating LUM-201 to treat pediatric growth hormone deficiency They also elaborated on the timeline of the further clinical development of LUM-201 The interview gives an understanding of Lumos Pharma’s vision to develop new therapies…
May 2, 2023
VIEWPOINTS_Bettina Cockroft_2023
Bettina Cockroft, SVP & CMO at Sangamo Therapeutics Shares Insights from the Positive P-I/II Data for Fabry Disease Treatment
Shots: Bettina gave the details of the study design and shared the preliminary results from the P-I/II STAAR clinical study evaluating ST-920. The data were presented in an oral presentation at the 29th Congress of the European Society of Gene & Cell Therapy 2022  She also talked about enzyme replacement therapy (ERT) which is currently used for the…
April 24, 2023
VIEWPOINTS_Paul K Owens_2023
Paul K Owens, VP of Global Brand Development, Insulins & Glucagon at Eli Lilly & Company Shares Insights from the US FDA Approval of Lyumjev
Shots: Paul talked about the approval of the Lyumjev Injection for the improvement of glycemic control in children and adolescents with diabetes. He also shared various details about Lyumjev Paul further discussed the study design and the key findings from the registrational PRONTO-Peds study The interview also talks about Lilly’s Diabetes Solution Center which helps eligible…
April 20, 2023
VIEWPOINTS_James Graham_2023
James Graham, CEO of Recce Pharmaceuticals Shares Insights from the Expansion and Acceleration of Clinical Programs
Shots: James gave an overview of the timeline of Recce Pharmaceuticals' clinical programs with several significant data read-outs in 2022 and 2023 He emphasized the study design and results from the different infectious disease clinical and preclinical programs in its product portfolio The interview highlights how the development and commercialization of New Classes of Synthetic Anti-Infectives…
April 18, 2023
VIEWPOINTS_Daniel Quirk_2023
Daniel Quirk, SVP, Head of US Medical Affairs at Bristol Meyers Squibb Shares his Views on the US FDA Approval of Sotyktu
Shots: Daniel started the discussion by speaking about the epidemiology of plaque and briefed about SOTYKTU approved for the treatment of moderate-to-severe Plaque Psoriasis He also elaborated on the results from the P-III registrational studies POETYK PSO-1 and POETYK PSO-2 The interview also talks about how BMS is advancing its product portfolio to deliver innovative…
April 17, 2023
Load more